MMF Shows Promise in Juvenile Scleroderma - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MMF Shows Promise in Juvenile Scleroderma

Mycophenolate mofetil demonstrated comparable disease control with fewer adverse effects.

  • By

  • Kathryn Wighton

  • February 2, 2026

  • 3 min

Share

Objective:

To compare the effectiveness and tolerability of mycophenolate mofetil (MMF) and methotrexate (MTX) in treating juvenile localized scleroderma (JLS).

Approach:
    Key Findings:
    • Both MMF and MTX achieved inactive disease status within 12 months with no significant differences in improvement rates.
    • MMF demonstrated significantly fewer adverse effects compared to MTX, including lower rates of nausea, fatigue, anxiety, and anticipatory vomiting.
    • Disease flare occurred in 25% of patients overall, with no significant differences in flare-free survival between treatment groups.
    Interpretation:

    These findings suggest that MMF may be a viable first-line treatment option for JLS, offering similar efficacy to MTX with improved tolerability.

    Limitations:
    • Retrospective, nonrandomized design with unequal treatment group sizes.
    • MMF was often initiated after longer disease duration or MTX intolerance, potentially biasing response estimates.
    • Adverse effects were assessed through clinical interviews rather than validated measures.
    • The study was not powered to detect small differences in efficacy.
    Conclusion:

    Prospective, randomized, noninferiority trials are needed to confirm these findings and inform future treatment guidelines.

    Sources:

Original Source(s)

MMF Shows Promise in Juvenile Scleroderma

  • by Kathryn Wighton

  • February 2, 2026

Related Content

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options